

PRESS RELEASE – FOR IMMEDIATE RELEASE

IntegraGen announces 12% growth in revenues in 2014

- **Strong growth in genomic services: 12% in the last 12 months**

Successful installation of the first high-throughput sequencing platform to guide the care of patients in clinical studies to receive the most appropriate targeted therapies.

Financing and launch of the ICE project which will develop software to assist in the interpretation of genomic data.

- **Confirmation of predictive role of the miRNA biomarker miR-31-3p in the response to anti-EGFR treatment in metastatic colorectal cancer**

EVRY, France (January 13, 2015) - IntegraGen (FR0010908723 - ALINT - PEA Eligible SMEs), which specializes in deciphering human genomic data and the associated analysis and rapid interpretation of information for academic and private laboratories, today announced its sales revenue for 2014.

<i>in Thousand €</i>	2014	2013	Var. %
Revenues*	6,036	5,408	+12 %

* excluding sales by the US subsidiary, unconsolidated

After a first half marked by a slight decline in revenues (-3%), IntegraGen benefited from a dynamic increase in genomic services activity during the second half of 2014. This resulted, in part, from the introduction of the sequencing platform in May at the Institute Gustave Roussy, the leading center for the management of cancer in Europe. Beyond the operational and financial performance, 2014 was marked by the launch of the ICE project which is developing software to assist in the interpretation of genomic data in oncology (supported by the state and local governments in the amount of € 2.5 m) in partnership with Gustave Roussy, Sogeti High Tech and INSERM. In oncology, the implementation of cooperative studies with the IFCT and with the investigators from the PICOLLO trial should allow the continuation of the prospective validation of the miR-31-3p biomarker. IntegraGen also successfully completed a capital increase and a transfer to the public compartment Alternext in June raising € 4.6 m in an offer which was two times oversubscribed.

"We are particularly proud of the double-digit growth in revenues achieved in 2014," stated Dr. Bernard Courtieu, IntegraGen's CEO. "The year was successful from both an operational and financial perspective with the revenue results we obtained firmly demonstrating the contributions from the IntegraGen team. As a result of setting up our first successful external high-speed sequencing unit for clinical research purposes in Europe, we have expanded our business offerings to now include genomic services to healthcare centers. We also completed several studies which confirm the clinical utility of our oncology biomarkers which will support our business strategy in this area during 2015. In autism, the availability of a new version of our autism risk test in the U.S. in early 2014 generated an increase in demand for the test. Finally, in financial terms, the successful capital increase in June confirms the support for funding of

our developments in oncology and autism. The year 2015 will be another busy year for IntegraGen with the deployment of new offers and the acceleration of our partnership strategy for diagnostic activities.”

ABOUT INTEGRAGEN

IntegraGen is a company specialized in deciphering the human genome by performing genomic analyses for academic and private laboratories and developing diagnostic tools within the fields of oncology and autism. IntegraGen’s oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. For autism, IntegraGen has developed the ARISK® Test, the first test marketed in the United States to assess the risk of autism spectrum disorder in children.

As of December 31, 2014, IntegraGen had 30 employees and generated revenue of €6 million in 2014. Based in the Evry Genopole, Integragen also has an office in the Cambridge, Massachusetts in the United States. IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - Eligible for PEA-SMEs).

For more information on IntegraGen visit www.integragen.com.



CONTACTS

INTEGRAGEN

Bernard COURTIEU
President, Managing Director

Laurence RIOT LAMOTTE
Directeur Administratif et Financier
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

NEWCAP.

Investor and Media relations

Louis-Victor DELOUVRIER
Nicolas MERIGEAU
integragen@newcap.fr
Tel.: +33 (0)1 44 71 94 94